Barinthus Biotherapeutics(BRNS) Stock Price Today

US Stock MarketDetailed Quotes

Barinthus Biotherapeutics (BRNS)

Watchlist

0.6000
+0.0085+1.44%

Close Mar 12 15:59 ET

0.5850
-0.0150-2.50%

Post 17:09 ET

24.50MMarket Cap-0.32P/E (TTM)

BRNS Stock Chart

After-Hours

5D
Daily
Weekly
Monthly
1Q
1Y

BRNS Orderflow

Unit: --

BRNS Orderflow Trend

IntradayDayWeekMonth

No Data

Barinthus Biotherapeutics (BRNS) News

12 Health Care Stocks Moving In Tuesday's After-Market Session
BenzingaMar 10 17:06 ET
Barinthus Biotherapeutics Amends Cross-Border Merger Agreement Terms
TipRanksFeb 23 06:32 ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
BenzingaFeb 10 07:05 ET
Express News | Barinthus Biotherapeutics Receives Nasdaq Noncompliance Notification, Gets Time Through June 20 To Regain Compliance
BenzingaJan 6 16:11 ET
H.C. Wainwright Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Maintains Target Price $4
Moomoo NewsDec 11, 2025 06:31 ET · Ratings
Promising Clinical Trial Results and Strategic Merger Drive Buy Rating for Barinthus Biotherapeutics
TipRanksDec 11, 2025 06:16 ET · Ratings

Barinthus Biotherapeutics (BRNS) Stock Forum

Moomoo Whale Watch

Feb 14 13:14

Columns Google Q4 13F Holdings: Standing Pat on Space, Exiting Biotech

As of December 31, 2025, $Alphabet-C (GOOG.US)$'s (Google's parent company) investment portfolio had a total market value of approximately $2.58 billion, up 7.05% from $2.41 billion in Q3. The portfolio holds 37 positions, with the top 10 holdings accounting for 92.81% of total assets, indicating a highly concentrated investment strategy. $AST SpaceMobile (ASTS.US)$ remains the top holding.
The portfolio displayed a unique "passive app...

Trytosaveabit

Dec 10, 2025 21:04

news

$Barinthus Biotherapeutics (BRNS.US)$ Barinthus Bio Issues Update On First-In-Human Phase 1 Trial Of VTP-1000 In Adults With Celiac Disease
Benzinga
1m
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trial
VTP-1000 was well-tolerated with no treatment-related SAEs
The MAD portion of the trial, which includes a gluten challenge, is ongoing
GERMANTOWN, Md., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Barinthus B...

Trytosaveabit

Nov 13, 2025 08:19

KK Dis is all the Heads-up you’re getting! Hehehe At least tonight anyways! Hehehe!

$Barinthus Biotherapeutics (BRNS.US)$ Never R/S! And not a risk anytime soon! That sets this up nicely IMO! But, BUT NFA Dis is ALL YOU DAWG! Hehehe! Anyways heres your Heads-Up! ENJOY! Hehehe
((((. Phase 1 AVALON trial of VTP-1000 in patients with celiac disease
•Part A: Single ascending dose (“SAD”):
•SAD is ongoing with no treatment related serious adverse events (“SAEs”) reported.
•Data expected to be announ...